LetterReply
Section snippets
To the editor:
We thank Dr Prince and colleagues for their critical comments and the report of failure to liposomal encapsulated doxorubicin in two cases of cutaneous T-cell lymphoma (CTCL). Every new treatment needs a good portion of criticism, and it is the same with the old compound doxorubicin delivered by a new technology, the pegylated liposomes. Prince et al raise 4 main questions:
- 1.
Do all patients with CTCL respond to the new doxorubicin formulation? The answer is no. In our pilot study1 including 6
References (2)
- et al.
Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin
J Am Acad Dermatol
(2000) Anthracyclines in the treatment of cancer: an overview
Drugs
(1997)
Cited by (0)
Copyright © 2001 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.